• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Orthocell

Report: Orthocell halts ASX trading in advance of $7m equity round

May 29, 2019 By Fink Densford

Orthocell (ASX:OCC) halted trading of its stocks on the Australian Securities Exchange yesterday, according to a Kalkine Media report. The trading stop came on the heels of a new equity raise for the company, which was launched through stockbroker Bell Potter Securities, according to a separate report on The Australian Financial Review. The Australian company is […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Orthocell

Orthocell wins CE Mark for CelGro device

November 13, 2017 By Sarah Faulkner

Orthocell (ASX:OCC) said today that its CelGro collagen medical device won CE Mark approval for a range of dental bone and soft tissue regeneration procedures. The company said it’s in talks with the strategic commercial partners to distribute its product throughout Europe and other key regions. Orthocell is also reportedly holding discussions with key opinion leaders […]

Filed Under: Dental, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Orthocell

7 medtech stories we missed this week: Oct. 13, 2017

October 13, 2017 By Danielle Kirsh

From Orthocell’s distribution deal to CorNeat unveiling its artificial cornea, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. OrthoCell inks Australian distro deal Orthocell announced in an Oct. 10 press release that it has signed a distribution deal with Surgical Specialities. The deal will make Surgical Specialities the […]

Filed Under: 510(k), Business/Financial News, Clinical Trials, Cosmetic/Aesthetic, Food & Drug Administration (FDA), Implants, Patient Monitoring, Regulatory/Compliance, Research & Development Tagged With: Alcon, Bonesupport, CorNeat, Faxitron, Masimo, MedTech, Orthocell, Viveve Medical

Orthocell touts CelGro nerve regeneration study

February 22, 2017 By Sarah Faulkner

Orthocell (ASX:OCC) touted interim data today from an ongoing clinical study of its CelGro collagen soft tissue repair device for peripheral nerve regeneration. Researchers are evaluating the safety, tolerability and effectiveness of CelGro in surgery with patients who have suffered injury to 1 or more peripheral nerves in the hand and upper limb. The company said that […]

Filed Under: Clinical Trials, Orthopedics, Regenerative Medicine, Surgical, Wall Street Beat Tagged With: Orthocell

Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment

January 12, 2017 By Sarah Faulkner

Orthocell (ASX:OCC) said today that it landed a research collaboration deal with Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes for its Ortho-ATI stem cell regenerative therapy. The 2 groups are planning a collaborative study for the 1st quarter in 2017, led by Allan Wang from the University of Western Australia. In previous studies, Ortho-ATI has proven […]

Filed Under: Drug-Device Combinations, Regenerative Medicine, Research & Development, Stem Cells, Wall Street Beat Tagged With: depuysynthes, Johnson and Johnson, Orthocell

Orthocell wins ethics nod for CelGro trial in peripheral nerve regeneration

October 18, 2016 By Sarah Faulkner

Orthocell (ASX:OCC) said today that it won ethics approval for a human study evaluating its CelGro collagen soft tissue repair device for peripheral nerve regeneration. The study is slated to enroll 20 patients at St. John of God Hospital at the end of the calendar year. Researchers will evaluate the safety, tolerability, and effectiveness of CelGro […]

Filed Under: Clinical Trials, Orthopedics, Regenerative Medicine, Surgical Tagged With: Orthocell

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy